For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Japan Could Get Left Behind in New Age of Open Innovation: Dr Fujimoto of Eli Lilly Japan
January 21, 2013
- Maruho to License Infantile Hemangioma Treatment from French Company
January 18, 2013
- Teijin Pharma Launches Acromegaly Treatment Somatuline
January 18, 2013
- Celgene K.K. Focused on MR Training Aiming for No. 1 Ranking Among Hematologists in 2013
January 18, 2013
- Ethical Drug Sales Up 2.4% in November: Crecon Report
January 18, 2013
- OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
- AZ K.K. President Hudson to Leave, Operations in Japan under Control of UK CFO
January 17, 2013
- Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
- Tivantinib Fails to Meet Primary Endpoint in PII Trial for Colorectal Cancer: Daiichi Sankyo
January 17, 2013
- Epadel Fails to Meet Endpoint in PII Trial with NASH Patients
January 16, 2013
- Eisai's Farletuzumab Fails to Meet Primary Endpoint in PIII Trial
January 16, 2013
- Otsuka Files for Approval for New Dry Powder Inhaler of Meptin
January 16, 2013
- GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
- Astellas and Sanwa Kagaku Launch Hyperkalemia Treatment Argamate Granule
January 15, 2013
- Different Reactions from Industry Following Announcement of Stricter Requirements on Sales of Epadel OTC
January 15, 2013
- Takeda Launches Hyperlipidemia Treatment Lotriga
January 11, 2013
- Eisai Ties Up with Epizyme, RMS to Develop a Companion Diagnostic
January 11, 2013
- Seiichiro Matsumura Serves as New President of Alcon Japan
January 11, 2013
- Nichi-Iko Voluntarily Recalls Picillibacta IV Inj. 1.5 g
January 11, 2013
- Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…